Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 31:6:174.
doi: 10.3389/fmed.2019.00174. eCollection 2019.

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies

Yumi Kambayashi  1 , Taku Fujimura  1 , Takanori Hidaka  1 , Setsuya Aiba  1
Affiliations
Review

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies

Yumi Kambayashi et al. Front Med (Lausanne). .

Abstract

Therapeutic options for treating advanced melanoma are progressing rapidly. Although anti-programmed cell death 1 (PD1) antibodies (e.g., nivolumab, pembrolizumab) have been approved as first-line and anchor drugs, respectively, for treating advanced melanoma, the efficacy appears limited as we expected, especially in Asian populations. Biomarkers to predict or evaluate the efficacy of anti-PD1 antibodies are needed to avoid subjecting patients to potentially severe adverse events associated with switching to other anti-melanoma drugs. This review focuses on the recent development of biomarkers for assessing the efficacy of anti-PD1 antibodies using routine blood tests such as the neutrophil-to-lymphocyte ratio, eosinophil ratio, serum markers such as lactate dehydrogenase, programmed cell death ligand 1 (PD-L1) expression on melanoma cells, microsatellite instability and mismatch repair deficiency assays, as well as soluble CD163, and tumor-associated macrophage-related chemokines (e.g., CXCL5, CXCL10).

Keywords: LDH; MSH; TAM-related factors; TMB; anti-PD1 antibodies; routine blood test.

PubMed Disclaimer

References

    1. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. (2017) 357:409–13. 10.1126/science.aan6733 - DOI - PMC - PubMed
    1. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. . Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. (2017) 171:934–49. 10.1016/j.cell.2017.09.028 - DOI - PMC - PubMed
    1. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, et al. . PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III Melanoma. Clin Cancer Res. (2016) 22:3915–23. 10.1158/1078-0432.CCR-15-1714 - DOI - PubMed
    1. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. (2016) 351:1463–9. 10.1126/science.aaf1490 - DOI - PMC - PubMed
    1. Fujimura T, Hidaka T, Kambayashi Y, Aiba S. BRAF kinase inhibitors for the treatment of melanoma: developments from early stage animal studies to phase II clinical trials. Exp Opin Invest Drugs. (2019) 28:143–8. 10.1080/13543784.2019.1558442 - DOI - PubMed